 Seventeen abstracts debut new data across narcolepsy and idiopathic hypersomnia DUBLIN , June 1, 2022 PRNewswire -- Jazz Pharmaceuticals plc Nasdaq: JAZZ today announced that the Company and its partners will present 17 new abstracts from across its neuroscience portfolio at SLEEP 2022, the 36th annual meeting of the Associated Professional Sleep Societies APSS being held June 4-8, 2022. Our latest research being presented at SLEEP 2022 provides important insights that benefit people living with complex and severe sleep disorders, deepening our understanding of these debilitating conditions and their overarching effects on patients, said Kelvin Tan, MB BCh, MRCPCH, senior vice president and chief medical officer of Jazz Pharmaceuticals. 